Coffey DS. Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol. 1998;81(suppl 1):1-5.
Djavan B. α-Adrenoceptor Antagonists for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): State of the Art. Department of Urology, University of Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ. Tamsulosin 0.4 mg Once Daily: Effect on Sexual Function in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction. Eur Urol. 1999;36:335-341.
Hong SJ, Rayford W, Valiquette L, Emberton M, The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. Br J U Int. 2005;95:15-19.
Narayan P. Long-term Safety and Efficacy of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms associated with Benign Prostatic Hyperplasia. From the North Florida Research Institute, Inc., Gainesville, FL. August 2003.
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
